# Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

> **NCT02795819** · PHASE1 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 6 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Metastatic Disease

## Interventions

- **DRUG:** AR-42
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT02795819
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-08
- **Primary completion:** 2016-11-24
- **Final completion:** 2019-03-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study drug no longer being clinically developed by manufacturer
- **Last updated:** 2019-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795819, "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02795819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*